Professional Services
Alzheimer's Drug News: Phase 3 Clinical Trial Update
Get the latest news on a potential new treatment for moderate to severe Alzheimer's patients. ELND005 has shown promising results in reducing agitation and aggression in Phase 2 trials and is now on the FDA's fast track for approval.